Data / Drug companies / Azacitidine
Azacitidine: 20 companies and 26 products in the FDA NDC directory
Azacitidine is listed in the FDA National Drug Code Directory by 20 companies, with 26 products in commercial distribution. 22 of the products (84.6%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, powder, lyophilized, for solution; tablet, film coated, and the newest product started marketing on August 29, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 20
- Products
- 26
- Generic (ANDA) products
- 22 (84.6%)
- Application numbers
- 15
- Routes
- Subcutaneous, Intravenous, Oral
- Brand names
- Onureg, Vidaza
- openFDA record search
- api.fda.gov
Companies that list azacitidine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Celgene Corporation | 3 | tablet, film coated; injection, powder, lyophilized, for solution | New drug applications (NDA) | September 1, 2020 |
| Dr. Reddy's Laboratories Inc. | 3 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 13, 2017 |
| BluePoint Laboratories | 2 | injection, powder, lyophilized, for solution | New drug applications (NDA) | January 10, 2025 |
| Meitheal Pharmaceuticals Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 2, 2020 |
| Accord Healthcare Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 9, 2019 |
| Amneal Pharmaceuticals LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | February 9, 2022 |
| Apotex Corp. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 23, 2024 |
| Armas Pharmaceuticals Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 10, 2018 |
| Camber Pharmaceuticals, Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 15, 2024 |
| Civica, Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 16, 2024 |
| Dr. Reddy's Laboratories Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 1, 2025 |
| Eugia US LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 3, 2023 |
| Fresenius Kabi USA, LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 16, 2017 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 8, 2020 |
| MSN Laboratories Private Limited | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 16, 2024 |
| NorthStar Rx LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 8, 2019 |
| Panacea Biotec Limited | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 6, 2019 |
| Reliance Life Sciences Private Limited | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 30, 2025 |
| Sandoz Inc | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 16, 2024 |
| Somerset Therapeutics, LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 29, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 24 | 92.3% |
| Tablet, film coated | 2 | 7.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 22 | 84.6% |
| New drug applications (NDA) | 4 | 15.4% |
Pharmacologic classes
| Class | Products |
|---|---|
| Nucleoside Metabolic Inhibitor | 26 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.